DORIAN THERAPEUTICS, INC.

San Carlos, CA · Biotech · Acquired

Small molecule USP16 inhibitor for intra-articular injection to treat osteoarthritis

doriantherapeutics.com →
Grants
$2.8M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Epigenetic modulation of cellular aging to improve CAR-T therapy for solid tumors$335,648
Federal grantDepartment of Health and Human Services · Phase II · Small molecule targeting an epigenetic regulator for the treatment of osteoarthritis$2,489,378
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3243Alchemab Therapeutics——
3244Abdera Therapeutics——
3245HocusLocus Inc.——
3246DORIAN THERAPEUTICS, INC.——
3247TARGEAD SCIENCES, INC.——
3248SYMBIOTICA, INC.——
3249SCI-ENGI-MEDCO SOLUTIONS, INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Methods And Compositions For Modulating Cellular Agingapplication
  • Compounds For Treatment Of Osteoarthritisapplication
  • Compounds For Treatment Of Osteoarthritisapplication
  • Methods And Compositions For Modulating Cellular Agingapplication
  • Methods And Compositions For Modulating Cellular Agingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.